Healthy people 2010: Challenges, opportunities, and a call to action for America's pharmacists

Pharmacotherapy

Volumn 24, Issue 9, 2004, Pages 1241-1294

  Calis, Karim Anton ^a   Hutchison, Lisa C ^b   Elliott, Mary E ^b   Ives, Timothy J ^b   Zillich, Alan J ^b   Poirier, Therese ^b   Townsend, Kevin A ^b   Woodall, Betsy ^b   Feldman, Stuart ^b   Raebel, Marsha A ^b  

^a American Coll of Clinical Pharmacy   (United States)

^b NONE

Author keywords

ACCP White Paper; Disease prevention; Health promotion; Healthy People 2010; Pharmacist's role

Indexed keywords

ALTEPLASE; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ERYTHROPOIETIN; VASODILATOR AGENT;

AMBULATORY CARE; ANEMIA; ARTHRITIS; ASTHMA; BACKACHE; BEHAVIOR MODIFICATION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; CIGARETTE SMOKING; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DIALYSIS; DRUG SAFETY; EMERGENCY TREATMENT; FAMILY PLANNING; GRAFT REJECTION; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNIZATION; INSULIN TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MENTAL DISEASE; METERED DOSE INHALER; NEPHROTOXICITY; OROPHARYNX CARCINOMA; OSTEOPOROSIS; PATIENT CARE; PATIENT COUNSELING; PHARMACIST; PHARMACY; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SKIN CANCER; SLEEP APNEA SYNDROME; SMOKING CESSATION; STROKE; TOBACCO DEPENDENCE;

ADULT; FEMALE; GOALS; HEALTH PROMOTION; HUMANS; MALE; PHARMACISTS; PREVENTIVE HEALTH SERVICES; PROFESSIONAL ROLE; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 4344644598     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.13.1241.38082     Document Type: Review

References (405)

1. American College of Physicians-American Society of Internal Medicine. Pharmacist scope of practice. Ann Intern Med 2002;136:79-85.
2. Hatoum HT, Catizone C, Hutchinson RA, et al. An 11-year review of the pharmacy literature: documentation of the value and acceptance of clinical pharmacy. Drug Intell Clin Pharm 1986;20:33-48.
3. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother 1999;33:1336-55.
4. Boyko WL Jr, Yurkowski PJ, Ivey MF, Armistead JA, Roberts BL. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm 1997;54:1591-5.
5. Willet MS, Bertch KE, Rich DS, et al. Prospectus on the economic value of clinical pharmacy services: a position statement of the American College of Clinical Pharmacy. Pharmacotherapy 1989;9:45-56.
6. Schumock GT, Meek P, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services: 1988-1995. Pharmacotherapy 1996;16:1188-208.
7. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23:113-32.
8. Leape LL, Cullen DJ, Clapp M, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
9. Pickard AS, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother 1999;33:1167-72.
10. Gattis WA, Hasselbla V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study. Arch Intern Med 1993;159:1939-45.
11. American College of Clinical Pharmacy-European Society of Clinical Pharmacy. Proceedings of the 1st international congress on clinical pharmacy. Documenting the value of clinical pharmacy services. April 11-14, 1999. Pharmacotherapy 2000;20(10 pt 2):233S-346.
12. Bond CA, Raehl CL, Franke T. Clinical pharmacy service and hospital mortality rates. Pharmacotherapy 1999;19:556-64.
13. Carmichael JM, O'Connell MB, Devine B, et al. Collaborative drug therapy management by pharmacists. Pharmacotherapy 1997;17:1050-61.
14. Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in health care (2002). Washington, DC: National Academy Press, 2002. Available from http://books.nap.edu/books/030908265X/html /index.html. Accessed May 23, 2002.
15. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62.
16. Kotecki JE, Fowler JB, German TC, Stephenson SL, Warnick T. Kentucky pharmacists' opinions and practice related to the sale of cigarettes and alcohol in pharmacies. J Community Health 2000;25:343-55.
17. O'Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med 1999;28:324-31.
18. Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(suppl 1):S45-51.
19. Siganga WW, Huynh TC. Barriers to the use of pharmacy services: the case of ethnic populations. J Am Pharm Assoc 1990;NS37:335-40.
20. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43
21. Straub LA, Straub SA. Consumer and provider evaluation of rural pharmacy services. J Rural Health 1999;15:403-12.
22. Watts PR, Dinger MK, Baldwin KA, Sisk RJ, Brockschmidt BA, McCubbin JE. Accessibility and perceived value of health services in five western Illinois rural communities. J Community Health 1999;24:147-57.
23. Knapp KK, Paavola FG, Maine LL, Sorofman B, Politzer RM. Availability of primary care providers and pharmacists in the United States. J Am Pharm Assoc 1999;39:127-35.
24. Hatoum JT, Akhras K. A 32-year literature review on the value and acceptance of ambulatory care provided by pharmacists. Ann Pharmacother 1993;27:1106-19.
25. Ernst ME, Chalstrom CV, Currie JD, Sorofman B. Implementation of a community pharmacy-based influenza vaccination program. J Am Pharm Assoc 1997;NS37:570-80.
26. Hoeben BJ, Dennis MS, Bachman RL, et al. Role of the pharmacist in childhood immunizations. J Am Pharm Assoc 1997;NS37:557-62.
27. Roth MT, Westman EC. Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. Pharmacotherapy 2001;21:636-41.
28. Melnyk PS, Shevchuk YM, Remillard AJ. Impact of the dial access drug information service on patient outcome. Ann Pharmacother 2000;34:585-92.
29. Mayer JA, Slymen DJ, Eckhardt L, et al. Skin cancer prevention counseling by pharmacists: specific outcomes of an intervention trial. Cancer Detect Prev 1998;22:367-75.
30. Lucato GS, Gardner JS, Koepsell TD. Adolescents' use of emergency contraception provided by Washington State pharmacists. J Pediatr Adolesc Gynecol 2001;14:163-9.
31. Paris W, Dunham S, Sebastian A, Jacobs C, Nour B. Medication nonadherence and its relation to financial restriction. J Transpl Coord 1999;9:149-52.
32. Schaefer B, Cone S. Increasing awareness of osteoporosis: a community pharmacy's experience. US Pharm 1998;23:72-85.
33. Farina RD, Corbett AH, Edwards MD, Kendrick SM. Osteoporosis screening: is screening effective? Can it be done economically? Will people pay for it? US Pharm 1999;24:38-43.
34. Pauley TR, Magee MJ, Cury JD. Pharmacist-managed, physician-directed asthma management program reduces emergency department visits. Ann Pharmacother 1995;29:5-9.
35. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
36. McGill KA, Sorkness CA, Ferguson-Page C, et al. Asthma in non-inner city Head Start children. Pediatrics 1998;102:77-83.
37. Baran RW, Crumlish K, Patterson H, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health-Syst Pharm 1999;56:1535-9.
38. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual 2000;15:137-42.
39. Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist managed diabetes service. J Manag Care Pharm 2000;6:488-93.
40. Yanchick JK. Implementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health-Syst Pharm 2000;57(suppl 4):S30-4.
41. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
42. Shibley MCH, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997;31:713-19.
43. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of managed pharmaceutical care on resource utilization and outcomes in Veterans Affairs medical centers. Pharmacotherapy 2000;20:1508-16.
44. Dumo P. Development and implementation of a pharmacist managed patient assistance program [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:PRC-2.
45. Dumo P, Sobotka PA. Impact of a pharmacist-managed patient assistance program (PAP) on cholesterol levels in an indigent population [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-339E.
46. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
47. Sims JJ. The role of the pharmacist in the management of heart failure. J Pharm Soc Wisconsin 2002;Jan-Feb:22-5.
48. Chisholm MA, Reinhardt BO, Vollenweider LJ, Kendrick BD, DiPiro JT. Medication assistance programs for uninsured and indigent patients. Am J Health-Syst Pharm 2000;57:1131-6.
49. Lamsam GD, Stone BA, Rumsey T, Shevlin JM, Scott BE, Reif CJ. Pharmaceutical services for a homeless population. Am J Health-Syst Pharm 1996;53:1426-30.
50. Weiner S, Dischler J, Horvitz C. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program. Am J Health-Syst Pharm 2001;58:146-50.
51. Lehmann DF, Medicis JJ. A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services. J Clin Pharmacol 1998;38:783-91.
52. King DS, Wyatt SB, Wofford MR, et al. Improvement in blood pressure control through interdisciplinary medication assistance efforts in hypertensive patients with multiple metabolic syndrome [abstr]. Am J Hypertens 2000;13(pt 2):18A.
53. Liu MY, Jennings JP, Samuelson WM, Sullivan CA, Veltri JC. Asthma patients' satisfaction with the frequency and content of pharmacist counseling. J Am Pharm Assoc 1999;39:493-8.
54. Centers for Medicare and Medicaid Services. Health Insurance Portability and Accountability Act of 1996. Available from http://www.cms.hhs.gov/hipaa. Accessed May 4, 2002.
55. Kulynych J, Korn D. The effect of the new federal medical-privacy rule on research. N Engl J Med 2002;346:201-4.
56. Mazzuca SA, Brandt KD, Katz BP, Hanna MP, Melfi CA. Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with osteoarthritis of the knee. Arthritis Rheum 1999;42:1267-73.
57. Read RW, Krska J. Targeted medication review: patients in the community with chronic pain. Int J Pharm Prac 1998;6:216-22.
58. Peterson GM, Bergin JK, Nelson BJ, Stanton LA. Improving drug use in rheumatic disorders. J Clin Pharm Ther 1996;21:215-20.
59. Ernst ME, Doucette WR, Dedhiya SD, et al. Use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with musculoskeletal disorders. Pharmacotherapy 2001;21:988-97.
60. Elliott ME, Meek PD, Kanous NL, et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc 2002;42:101-10.
61. Newman ED, Hanus P. Improved bone health behavior using community pharmacists as educators: the Geisinger health system community pharmacist osteoporosis education program. Dis Manag Health Outcomes 2001;9:329-35.
62. Rosenthal WM. Implementing bone mineral density testing in the community pharmacy. J Am Pharm Assoc 2000;40:737-45.
63. Berardo DH. Pharmacists' practice opportunities in women's health. Pharm Prac Manag Q 1999;19:42-56.
64. Giles JT, Kennedy DT, Dunn EC, Wallace WL, Meadows SL, Cafiero AC. Results of a community pharmacy-based breast cancer risk-assessment and education program. Pharmacotherapy 2001;21:243-53.
65. Williamson JS. Counseling the patient on breast cancer therapy. Pharm Times 2000;66:30-31, 35-36.
66. Levy S. R.Ph.'s encouraged to expand breast cancer counseling. Drug Topics 1999;143:44.
67. Tau JH. Pharmacists vital in breast cancer battle. Drug Store News for the Pharmacist 1994;4:S7.
68. Sherman M. Breast cancer and the community setting. Pharm Times 1998;64:55-6.
69. Goodwin NJ, Fitzpatrick RW, Brunt AM. Impact on pharmacy staff utilization by the implementation of a standardized dosage system for an outpatient breast cancer chemotherapy regimen [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:21.
70. Bolinger BC, Iwata P, Demman Treinen A, Hart M, Russell C. Care pathway in oncology: pharmacy's impact in a breast cancer care pathway [abstr]. In: Program and abstracts of the 31st midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1996:63.
71. Francisco JA, Steinberg JR. Implementation of a critical pathway for autologous bone marrow transplantation in breast cancer and its impact on pharmacy practice in a comprehensive cancer center [abstr]. In: Program and abstracts of the 30th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1995:541.
72. Scully C, Gill Y, Gill Z. How community pharmacy staff manage a patient with possible oral cancer. Br J Oral Maxillofac Surg 1989;27:16-21.
73. Clark-Vetri R. Counseling the patient about prostate cancer. Pharm Times 2000;66:37-41.
74. DeAntoni E, Crawford ED. Prostate cancer awareness: what pharmacists need to know. Pharm Times 1993;59:29-30, 32, 35.
75. Mayer JA, Eckhardt L, Stepanskl BM, et al. Promoting skin cancer prevention counseling by pharmacists. Am J Public Health 1998;88:1096-9.
76. Mayer JA, Slymen DJ, Eckhardt L, et al. Skin cancer prevention counseling by pharmacists: specific outcomes of an intervention trial. Cancer Detect Prev 1998;22:367-75.
77. Mayer JA, Eckhardt L. Educating the public about skin cancer prevention: a role for pharmacists. J Clin Pharm Ther 1996;21:399-406.
78. Kilkenny M, Yeatman J, Stewart K, Marks R. Role of pharmacies and general practitioners in the management of dermatological conditions. Int J Pharm Pract 1997;5:11-15.
79. Board of Pharmaceutical Specialties. Certified pharmacists oncology pharmacists. Available from http://www.bpsweb.org. Accessed April 27, 2002.
80. National Heart, Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular disease, lung and blood diseases. Bethesda: Public Health Service, 1998.
81. Brown, G. Minimizing aminoglycoside toxicity by prescriber notification of prolonged therapy. Hosp Pharm 1995;30:33-6.
82. Cherry DK, Woodwell DA. National ambulatory medical care survey: 2000 summary. Advance data from vital and health statistics, no. 328, June 5, 2002. Available from http://www.cdc.gov/nchs/data/ad/ad328.pdf. Accessed July 7, 2004.
83. Brophy DF, Mueller BA. Automated peritoneal dialysis: new implications for pharmacists. Ann Pharmacother 1997;31:756-64.
84. Chisholm MA, Vollenweider LJ, Mulloy LL, Wynn JJ, Wade WE, DiPiro JT. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic. Clin Transplant 2000;14(4 pt 1):304-7.
85. Goldberg DE, Baardsgaard G, Johnson MT, Jolowsky CM, Shepherd M, Peterson CD. Computer-based program for identifying medication orders requiring dosage modification based on renal function. Am J Hosp Pharm 1991;48:1965-9.
86. Golightly LK, O'Fallon CL, Moran WD, Sorockl AH. Pharmacist monitoring of drug therapy in patients with abnormal serum creatinine levels. Hosp Pharm 1993;28:725-7, 730-2.
87. Grabe DW, Low CL, Ballie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997;47:117-21.
88. Hatoum H, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 1988;22:252-9.
89. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients. I. Characterization and drug-related problems. Ann Pharmacother 1994;28:316-19.
90. Kaplan B, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis patients. II. Reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 1994;28:320-4.
91. Matzke GR, St Peter WL, Comstock TJ, Foote EF. Nephrology pharmaceutical care preceptorship: a programmatic and clinical outcomes assessment. Ann Pharmacother 2000;34:593-9.
92. Fahre S. Nephrology pharmacy practice in the outpatient dialysis setting. Adv Renal Replacement Ther 1997;4:179-81.
93. Tang I, Vrahnos D, Hatoum H, Lau A. Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther 1993;15:459-64.
94. To LL, Stoner CP, Stolley SN, Buenviaje JD, Ziegler TW. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health-Syst Pharm 2001;58:2061-5.
95. Joy MS, Neyhart CD, Dooley MA. A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy 2000;20:206-16.
96. Robinson SN, Crane VS, Jones DG. Pharmaceutical services in an extracorporeal shock wave lithotripsy center. Am J Hosp Pharm 1987;44:799-802.
97. McMullin ST, Reichley RM, Kahn MG, Dunagan WC, Bailey TC. Automated system for identifying potential dosage problems at a large university hospital. Am J Health-Syst Pharm 1997;54:545-9.
98. Milan NL. Evaluation of drug prescribing in patients with renal dysfunction [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:P-280R.
99. 2-antagonist dosing in the elderly based on renal function [letter]. Ann Pharmacother 1992;26:1595.
100. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994;28:1335-9.
101. Berbatis CG, Eckert GM, Neale FG, Rothwell JP. Quality assurance of drug therapy in hospitals: patient serum creatinine values used by ward pharmacists in checking dosage regimens. Med J Aust 1979;1:46-7.
102. Saletnik BA. Implementation of a computer identification service for monitoring renal function in the outpatient FIRMS system [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:P-114R.
103. Susanka AL, Hancock DL, Losson M. Staff pharmacist program for adjusting dosages on basis of creatinine clearance. Am J Hosp Pharm 1993;50:909-10.
104. Champagne MP. Renal disease audit and drug usage evaluation for all patients. Hosp Pharm 1992;27:1065-7.
105. Peterson J, Colucci VJ, Schiff SE. Using serum creatinine concentrations to screen for inappropriate dosing of renally eliminated drugs. Am J Hosp Pharm 1991;48:962-4.
106. Roberts SR, Roberts TR. Cost savings associated with renal dosage adjustments of IV antibiotics by the pharmacist [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-266E.
107. Polovich BL, Hamilton JD. Antimicrobial renal dosing program in a community teaching hospital [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-265R.
108. Brodrick A, Edwards A, Wind K. Computer adjusted doses in renal impairment. Br J Pharmaceutical Pract 1981;2:4, 6-7.
109. Wong BJ, Chandler-Toufiell DM, Clark ST. Increasing pharmacists' interventions using computerized renal dosing drug rules [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-378D.
110. Danekas PL, Stoysich AM, Massoomi F, Neff WJ. Automatic renal dose adjustment program at a community hospital [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-604D.
111. Colodny LR, Amin K. Using pharmacy services to promote compliance with renal dosing of antibiotics. Hosp Form 1996;31:834-6, 841-2.
112. Ho C, Calmes H. Seven-year experience of a specialized renal-dosing service in a tertiary teaching facility [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-151D.
113. Montgomery PA, Kan JM, Schaad AL. Systematic interventions to reduce enoxaparin doses in renal dysfunction and lower the rate of bleeding [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-153E.
114. Abel SR, Guba EA. Evaluation of an imipenem/cilastatin target drug program. Drug Intell Clin Pharm 1991;25:348-50.
115. Guglielmo BJ, Jacobs RA. Impact of dosage-monitoring system on frequency of seizures associated with imipenen-cilastatin. Am J Health-System Pharm 1996;53:2097-8.
116. Lewis D, Cazes JJ, Namjoshi AA. Assessing the impact of a staff pharmacist intervention program for dosing imipenem/cilastatin in the renally impaired patient [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-172D.
117. McAslan MS, Jakubecz MA, Axtell SS, Vyas N. Implementation of a renal dose monitoring program to reduce potential adverse drug events [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-731D.
118. Rech GR. Pharmacist initiated medication dosing for renally compromised patients [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-296D.
119. Ting Y, Robinson JP. Computer-assisted drug dosage intervention in patients with elevated serum creatinine [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:P-156D.
120. Houshmand CM, Sketris I. A prospective evaluation and cost assessment of pharmacist monitoring of patients with renal dysfunction receiving selected drugs. Can J Hosp Pharm 1996;49:66-71.
121. Fields CE, McPherson ML, Metge CJ. Prescribing patterns of renally eliminated medications in a home health care population. Consultant Pharmacist 1996;11:135-40, 145-8.
122. Morrissey MR, Plein JB, Plein EM. Prospective review of dosing of renally eliminated medications for nursing home residents. Consultant Pharm 1991;6:623-38.
123. Moore MR, Labs AJ. Implementation of a renal dosing program in a community pharmacy setting. J Pharm Soc Wis 2002;Sept-Oct:19-23.
124. Portoles J. The beneficial effects of intervention in early renal disease. Nephrol Dial Transplant 2001;16(suppl 2):12-15.
125. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 2001;12:2465-73.
126. Turco TF. Health care outcomes case study: anemia in end-stage renal disease. Am J Health-Syst Pharm 1995;52(suppl 4):S19-23, S27-8.
127. Johnson CA. Therapeutic issues in patients on continuous ambulatory peritoneal dialysis [abstr]. In: Program and abstracts of the 33rd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1998:PI-106.
128. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF. Anemia management of adult hemodialysis patients in the US: results from the 1997 ESRD core indicators project. Kidney Int 2000;57:578-89.
129. Roberts MJ, Sipala M, DiBenedetto J. Implementation of a hospital policy for the cost-effective use of erythropoietin in anemia of chronic renal failure and anemia induced by chemotherapy or zidovudine [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-349E.
130. Miller E, Turco TF, Lum LR. Enhancing an epoetin alfa (EPO) pharmacy distribution system for dialysis patients [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:P-160D.
131. Qin M, Patel PB, Bach DS. Impact of pharmacy services in the end stage renal disease patient [abstr]. In: Program and abstracts of the 33rd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1998:P-387E.
132. Matzke GR, Cadogan AC, Kim JJ, et al. Pharmaceutical care in a university medical center-affiliated ambulatory dialysis center [abstr]. Pharmacotherapy 1999;19:518.
133. Skoutakis VA, Acchiardo SR, Martinez DR, Lorisch D, Wood GC. Role-effectiveness of the pharmacist in the treatment of hemodialysis patients. Am J Health-Syst Pharm 1978;35:62-5.
134. Scott CJ, Possidente CJ, Ahern JW. Development of dosing and monitoring guidelines for vancomycin during hemodialysis [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-352D.
135. Lomaestro BM, Bailie GR, Eisele G. Timeliness of medication administration in hemodialysis inpatients: drug use evaluation. Hosp Pharm 1993;28:980-2, 984.
136. Possidente CJ, Bailie GR, Hood VL. Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health-Syst Pharm 1999;56:1961-4.
137. Joy MS, Hollar KD, Neyhart CD, et al. Assessment of risk factors for bone disease in renal transplant recipients. J Pharm Technol 2002;18:54-62
138. Alexander AC. Treatment of ESRD patients with renal osteodystrophy and anemia. US Pharm 1997;22:HS21-30, HS33-4.
139. Abrahams RJ, DeStefano J, Quercia RA. Computerization of monitoring and dosing erythropoietin, iron dextran and calcitriol in the hemodialysis center [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:P-244D.
140. Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 2002;39:1270-7.
141. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant 2001;15:330-6.
142. Chisholm MA, Vollenweider LJ, Mulloy LL, Jagadeesan M, Wade WE, DiPiro JT. Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team. Am J Health-Syst Pharm 2000;57:1994-6.
143. Brown TER, Carter BL. Hypertension and endstage renal disease. Ann Pharmacother 1994;28:359-66.
144. Hatoum JT, Akhras K. A 32-year literature review on the value and acceptance of ambulatory care provided by pharmacists. Ann Pharmacother 1993;27:1106-19.
145. Carter BL, Elliott WJ. The role of pharmacists in the detection, management, and control of hypertension: a national call to action. Pharmacotherapy 2000;20:119-22.
146. Carter BL. Clinical pharmacy in disease-specific clinics. Pharmacotherapy 2999;20(10 pt 2):S273-7.
147. Godley P, Pham H, Rohack J, et al. Opportunities for improving the quality of hypertension care in a managed care setting. Am J Health-Syst Pharm 2001;58:1728-33.
148. Jones RM, Pincus KT. Managing the diabetic patient with renal failure. US Pharm 1996;21:HS3, HS6, HS9-10, HS13-4, HS16.
149. Berardl RR, DeSimone EM, Popovich NG, eds. Handbook of nonprescription drugs, 13th ed. Washington DC: American Pharmaceutical Association, 2002.
150. Carlisle BA. The implications of diabetes control and complications trial for the pharmacy profession. Ann Pharmacother 1996;30:294-5.
151. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002;39:297-307.
152. Bhattacharyya SK, Else BA. Medical costs of managed care in patients with type 2 diabetes mellitus. Clin Ther 1999;21:2131-42.
153. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977;34:1238-42.
154. Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures. J Manag Care Pharm 2002;8:48-53.
155. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
156. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
157. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 2002;2:134-47.
158. Raehl CL, Bond CA. 1998 National clinical pharmacy services study. Pharmacotherapy 2000;20:436-60.
159. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health-Syst Pharm 1995;52:1895-900.
160. Bonal J. Clinical pharmacy in inpatient care. Pharmacotherapy 2000;20(10 pt 2):S264-72.
161. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio heart study. Arch Intern Med 1999;159:1450-6.
162. Clark CM Jr. How should we respond to the worldwide diabetes epidemic? Diabetes Care 1998;21:475-6.
163. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
164. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes in the United States. Atlanta: U.S. Department of Health and Human Services, 1999.
165. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21:296-309.
166. Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med 1999;29:173-86.
167. Schapansky LM, Johnson JA. Pharmacists' attitudes toward diabetes. J Am Pharm Assoc 2000;40:371-7.
168. Younis WS, Campbell S, Slack MK. Pharmacists' attitudes toward diabetes and their involvement in diabetes education. Ann Pharmacother 2001;35:841-5.
169. Baran RW, Crumlish K, Patterson H, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health-Syst Pharm 1999;56:1535-9.
170. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc 1999;39:791-7.
171. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41.
172. Cooper JW. Consultant pharmacist contribution to diabetes mellitus patient outcomes in two nursing facilities. Consultant Pharm 1995;10:40-5.
173. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
174. Sadur CN, Moline N, Costa M, et al. Diabetes management in a health maintenance organization: efficacy of care management using cluster visits. Diabetes Care 1999;22:2011-17.
175. Sutherland JE, Hoehns JD, O'Donnell B, Wiblin RT. Diabetes management quality improvement in a family practice residency program. J Am Board Fam Pract 2001;14:243-51.
176. Tsuyuki RT, Johnson JA, Teo KK, et al. Study of cardiovascular risk intervention by pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999;33:910-19.
177. Yanchick JK. Implementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health-Syst Pharm 2000;57(suppl 4):S30-4.
178. Carter BL, Malone DC, Billups SJ, et al. Interpreting the findings of the IMPROVE study. Am J Health-Syst Pharm 2001;58:1330-7.
179. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care 2000;23(suppl 1):S1-116.
180. Boyd ST, Ramsey LA, Noble SL, Byrd HJ. Development and implementation of a comprehensive diabetes care module: overcoming the challenges of disease state management in community pharmacies [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:524D.
181. Daugherty KK. Pharmacist intervention in the management of type 2 diabetic patients: does it improve glycosylated hemoglobin and blood pressure control [abstr]? In: Program and abstracts of the annual meeting of the American Association of Colleges of Pharmacy. Alexandria: AACP, 2000;101:245.
182. Delinck PW, Leslie DM, Jovic M, Duvel JM, Clark CA. Impact of pharmacy initiated mail reminders to improve glycosylated hemoglobin testing [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:481R.
183. Grace KA, McPherson ML, Rosenbloom DM. Outcome analysis of a pharmacist-managed diabetes service [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:OUT-3.
184. Ike EN. Outcomes analysis of pharmacist involvement in the management of type 2 diabetic patients [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999:OUTF99-30.
185. Kinnon AL. Impact of clinical pharmacist intervention in the team management of diabetic patients: outcome assessment of LDL and hemoglobin A1c reduction in a VA medical center primary care outpatient clinic [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:9R.
186. Maffeo CM, Simitian LS, Chen SW. Impact of primary care pharmacy services on dyslipidemia management in diabetic patients [abstr]. In: Program and abstracts of the 33rd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1998:59R.
187. Morello CM, Engelbrecht EB, Cording MA, Agent SK. Evaluation of clinical outcomes of pharmacist managed type 2 diabetes clinics [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:331E.
188. Smedley EN. Improving diabetes management through dynamic pharmaceutical care [abstr]. In: Program and abstracts of the annual meeting of the American Association of Colleges of Pharmacy. Alexandria: AACP, 2000;101:246.
189. Soorapan S, Mackie CA, McCaig DJ, Stewart DC. Randomized controlled trial to determine whether pharmaceutical care can influence patient outcomes of type 2 diabetes in a general practice setting [abstr]. In: Program and abstracts of the 32nd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:INTL-35.
190. Speicher GA, Duong TT, Inciardi J. Impact of team management on patients with diabetes [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:546E.
191. Spitler JR, Berkeley KL, Oatis GM, Coomes VH, Stowers AD. Assessment of diabetes care in a pharmacist-run ambulatory care clinic [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:314R.
192. Toy CJ, Mitani GH, Gong WC, Harrison EC. Role of the pharmacist in managing diabetes in high-risk cardiac patients: descriptive report [abstr]. In: Program and abstracts of the 30th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1995:265D.
193. Vicki K, Smarinsky RA, Chung S, Ida JK. Evaluation of pharmacist-directed diabetes care in a community clinic [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999:316E.
194. Villarreal MC. Pharmacist managed thiazolidinedione monitoring service in a university ambulatory care clinic [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:MCS-27.
195. Watson AR, Carwithen J, Estoup M, Ives J. Clinical benchmarks of diabetic patients enrolled in a pharmacist-based self-management program [abstr]. In: Program and abstracts of the 36th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2001:652R.
196. Wright LM, Egbunike IG, Plattenburg P. Incorporation of a pharmacist into the diabetes education service within a multi-institutional healthcare system [abstr]. In: Program and abstracts of the 33rd midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1998:268E.
197. Yanchick J. Development of a multidisciplinary diabetes mellitus management team in the primary care setting [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999:MCS-9.
198. American Association of Diabetes Educators. Professional education. Board certified-advanced diabetes management. Available from http://www.aadenet.org/ ProfessionalEd/BCADM/AdvClinicalDMOverview.html. Accessed July 7, 2004.
199. Lande RE, Blackburn R. Pharmacists and family planning. Popul Rep J 1989;37:1-31.
200. American Pharmacists Association. Emergency contraception: the pharmacist's role. Available from http://www.pharmcare.org/cem/ EmergencyContraceptionProg ram.pdf. Accessed July 7, 2004.
201. Gardner JS, Hutchings J, Fuller TS, et al. Increasing access to emergency contraception through community pharmacies: lessons from Washington state. Fam Plann Perspect 2001;33:172-5.
202. Wells ES, Hutchings J, Gardner JS, et al. Using pharmacies in Washington state to expand access to emergency contraception. Fam Plann Perspect 1998;30:288-90.
203. Marciante KD, Gardner JS, Veenstra DL, et al. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health 2001;91:1443-5.
204. Sommers SD, Chaiyakunapruk N, Gardner JS, et al. Emergency contraception collaborative prescribing experience in Washington state. J Am Pharm Assoc 2001;41:60-6.
205. Montagne M. Research and evaluation in health communication. Am J Pharm Ed 1987;51:172-7.
206. Lewis RK, Lasack NL, Lambert BL, Connor SE. Patient counseling: a focus on maintenance therapy. Am J Hosp Pharm 1997;54:2084-98.
207. Morrow D. Improving consultations between health-care professionals and older clients: implications for pharmacists. Int J Aging Hum Dev 1997;44:47-72.
208. Collins KS, Hughes DL, Doty MM, Ives BL, Edwards JN, Tenney K. Diverse communities, common concerns: assessing health care quality for minority Americans. In: The Commonwealth Fund Report. New York: The Commonwealth Fund, March 2002.
209. Jackson LD, Duffy BK, eds. Health communication research. Westport, CT: Greenwood, 1998.
210. Eng TR, Gustafson DH, eds. Science panel on interactive communication and health. Wired for health and well-being: the emergence of interactive health communication. Washington, DC: Health and Human Services, U.S. Government Printing Office, 1999.
211. Maibach E, Parrott RL. Designing health messages. Thousand Oaks, CA: Sage Publications, 1995.
212. Atkin C, Wallack L, eds. Mass communication and public health. Newbury Park, CA: Sage Publications, 1990.
213. Backer TE, Rogers EM, Sopory P. Designing health communication campaigns: what works? Newbury Park, CA: Sage Publications, 1992.
214. Harris LM, ed. Health and the new media. Technologies transforming personal and public health. Mahwah, NJ: Lawrence Erlbaum Associates, 1995.
215. Street RL, Gold WR, Manning T, eds. Health promotion and interactive technology: theoretical applications and future directions. Mahwah, NJ: Lawrence Erlbaum Associates, 1997.
216. Finnegan JR Jr, Viswanath K. Health and communication: medical and public health influences on the research agenda. In: Ray EB, Donohew L, eds. Communication and health: systems and applications. Hillsdale, NJ: Lawrence Erlbaum Associates, 1990.
217. Gardner SF, Skelton DR, Rollins SD, et al. Community pharmacy databases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy 1995;15:292-6.
218. Gilutz H, Battler A, Rabinowitz I, et al. Door-to-needle blitz in acute myocardial infarction: impact of a CQI project. Joint Comm J Qual Improv 1998;24:323-33.
219. Schneider PJ, Larrimer JN, Visconti JA, et al. Role effectiveness of a pharmacist in the maintenance of patients with hypertension and congestive heart failure. Contemp Pharm Pract 1982;5:74-9.
220. Gattis WA, Hasselblad V, Whellan DJ, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
221. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health-Syst Pharm 1999;56:1339-42.
222. Turner CJ, Parfrey P, Ryan K, et al. Community pharmacist outreach program directed at physicians treating congestive heart failure. Am J Health-Syst Pharm 2000;57:747-52.
223. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001;161:2223-8.
224. McNicholl JJ, Porter J, Huff P. Heart failure management program in a group-model HMO. Am J Health-Syst Pharm 1999;56:2553-4.
225. Luzier AB, Forrest A, Feuerstein SG, et al. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol 2000;86:519-23.
226. Varma S, McElnay JC, Hughes CM, et al. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy 1999;19:860-9.
227. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998;158:1067-72.
228. Newell SA, Bowman JA, Cockburn JD. A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment-keeping in the treatment of cardiovascular disease. Prev Med 1999;29:535-48.
229. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications. In: The Cochrane Library, issue 2, 2004. Chichester, UK: John Wiley and Sons, Ltd.
230. Wilt VM, Gums JG, Ahmed OI, et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1996;15:732-9.
231. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed warfarin anticoagulation clinic. Drug Intell Clin Pharm 1985;19:575-80.
232. Garabedian-Ruffalo SM, Gray DR, Sax MJ, et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985;42:304-8.
233. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-7.
234. Carter BL, Elliott WJ. The role of pharmacists in the detection, management, and control of hypertension: a national call to action. Pharmacotherapy 2000;20:119-22.
235. Park JJ, Kelly P, Carter BL, et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996;NS36:443-51.
236. Carter BL, Barnette DJ, Chrischilles E, et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17:1274-85.
237. Carter BL. Clinical pharmacy in disease-specific clinics. Pharmacotherapy 2000;20(10 pt 2):S273-7.
238. Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc 1998;38:574-85.
239. Gourley GA, Portner TS, Gourley DR, et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc 1998;38:586-97.
240. Simpson SH, Johnson JA, Tsuyuki TS. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 2001;2:627-35.
241. Birtcher K, Bowden C, Ballantyne C, et al. Strategies for implementing lipid-lowering therapy: pharmacy based approach. Am J Cardiol 2000;85:A30-5.
242. Shimp LA, Mason NA, Toedter NM, et al. Pharmacist participation in cardiopulmonary resuscitation. Am J Hosp Pharm 1995;52:980-4.
243. Tseng A, Foisy M, Bajcar J, et al. Development of an HIV pharmacy practice specialty residency. Am J Health-Syst Pharm 2001;58:591-4.
244. Frick PA, Gal P, Lane TW, Sewell PC. Antiretroviral medication compliance in patients with AIDS. AIDS Patient Care STDS 1998;12:463-70.
245. Fung HB, Pecini RA, Brown ST. HIV pharmacotherapy clinic. Am J Health-Syst Pharm 1998;55:955-6.
246. Geletko SM, Poulakos MN. Pharmaceutical services in an HIV clinic. Am J Health-System Pharm 2002;59:709-13.
247. Colombo J. Establishing pharmaceutical care services in an HIV clinic. J Am Pharm Assoc 1997;NS37:581-92.
248. Foisy MM, Tseng A, Blaike N. Pharmacists' provision of continuity of care to patients with human immunodeficiency virus infection. Am J Health-Syst Pharm 1996;53:1013-17.
249. Haddad M, Inch C, Glazier RH, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2000;(3):CD001442.
250. Timmerman AM, Steadman MS. Establishment of an HIV consult team in a family practice clinic: role of a clinical pharmacist [abstr]. In: Program and abstracts of the 35th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-305E.
251. Warnock AC, Rimland D. The provision of pharmaceutical care in a Veterans' Affairs medical center outpatient HIV clinic. Hosp Pharm 1994;29:114-16, 119-20.
252. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS 1999;13:535-44.
253. Smith SR. Collaborations between case managers and pharmacists in HIV/AIDS care [abstr]. From the 129th annual meeting of the American Public Health Association, Atlanta, GA, October 21-25, 2001. Available from http://apha.confex.com/apha/129am/techprogram/paper_2987 7.htm. Accessed March 30, 2002.
254. Sheridan J, Strang J, Taylor C, Barber N. HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training. Addiction 1997;92:1737-48.
255. Myers T, Cockerill R, Worthington C, Millson M, Rankin J. Community pharmacist perspectives on HIV/AIDS and interventions for injection drug users in Canada. AIDS Care 1998;10:689-700.
256. Singer M, Himmelgreen D, Weeks MR, Radda KE, Martinez R. Changing the environment of AIDS risk: findings on syringe exchange and pharmacy sales of syringes in Hartford, CT. Med Anthropol 1997;18:107-30.
257. Gleghorn AA, Gee G, Vlahov D. Pharmacist's attitude about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr 1998;18(suppl 1):S89-93.
258. Cantwell-McNelis K, James C. Role of clinical pharmacists in outpatient HIV clinics. Am J Health-Syst Pharm 2002;59:447-52.
259. Ketih MR. Televideo technology for patient counseling and education. Am J Health-Syst Pharm 1999;56:860-1.
260. Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS 2000;14(suppl 1):S47-51.
261. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr 2001;28:273-8.
262. Marquardt WR, Harwell-Rice BA, Ennis SL, Kessler M, Carney SD. Pharmacy service in an inner-city indigent clinic [abstr]. In: Program and abstracts of the 57th annual meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:P-7.
263. American College of Clinical Pharmacy. Directory of residencies and fellowships. Available from http://www.accp.com/resandfel/directorynon.php. Accessed May 9, 2002.
264. Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions: 2001. J Am Board Fam Pract 2001;14:283-309.
265. Stergachis A. Roles for pharmacists in the prevention and control of sexually transmitted diseases. Sex Transm Dis 1999;26(suppl 4):S44-8.
266. Noormohamed SE, Ferguson KJ, Baghaie A, Cohen LG. Students' knowledge base and attitudes on safer sex, condoms, and AIDS: study of three colleges of pharmacy. Am J Pharm Educ 1994;58:269-73.
267. American Association of Colleges of Pharmacy. Number of first professional degrees (baccalaureate and Pharm.D.) conferred 1983-2003 by gender and race/ethnicity. Available from http://www.aacp.org/Docs/MainNavigation/ Institutional Data/4328-pps-table12.pdf. Accessed July 7, 2004.
268. Anonymous. ASHP technical assistance bulletin on the pharmacist's role in immunization. Am J Hosp Pharm 1993;50:501-5.
269. Grabenstein JD. Pharmacists and immunization: increasing involvement over a century. Pharm Hist 1999;41:137-52.
270. Nahata MC. Pharmacist's role in improving immunization status among preschool children. Ann Pharmacother 1994;28:952-3.
271. Madhavan S, Rosenbluth S, Amonkar M, et al. Pharmacists and immunizations: a national survey. J Am Pharm Assoc 2001;41:32-45.
272. Anonymous. ASHP statement on the pharmacist's role in infection control. Am J Health-Syst Pharm 1998;55:1724-6.
273. ASHP Commission on Therapeutics. ASHP therapeutic position statement on identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults. Am J Health-Syst Pharm 2991;58:331-7.
274. Barriere SL, Dudley MN, Kowalsky SF, et al. The role of the pharmacist in antimicrobial agent therapy. J Infect Dis 1989;159:593-4.
275. Strayer AH. Society of Infectious Diseases Pharmacists (SIDP) position papers. Pharm Pract Manage Q 1996;16:62-5.
276. Grabenstein J, Guess H, Hartzema A. People vaccinated by pharmacists: descriptive epidemiology. J Am Pharm Assoc 2001;41:46-52.
277. Kamal KM, Madhavan SS, Maine LL. Pharmacy and immunization services: pharmacists' participation and impact. J Am Pharm Assoc 2003;43:470-82.
278. Joish VN, Limcangco RM, Armstrong EP. Cost benefit analysis of a pharmacists advocated pneumococcal vaccination program. Hosp Formul 2001;36:147, 151-2, 155-6.
279. Grabenstein JD, Hartzema AG, Guess HA, Johnston WP, Rittenhouse BE. Community pharmacists as immunization advocates: cost-effectiveness of a cue to influenza vaccination. Med Care 1992;30:503-13.
280. Dickerson LM, Mainous AG, Carek PJ. Pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy 2000;20:711-23.
281. Forster K, Koo J, Heyworth MF. A pharmacist-managed Helicobacter pylori VAMC clinic. Pharmacol Ther 1999;24:184-7.
282. Coleman LT, Adams WC, Gong WC. Pharmacist as a primary care provider in a tuberculosis clinic. Am J Hosp Pharm 1983;40:278-81.
283. Hurtig AK, Pande SB, Baral SC, Porter JD, Bam DS. Anti-tuberculosis treatment in private pharmacies, Kathmandu Valley, Nepal. Int J Tuberc Lung Dis 2000;4:730-6.
284. Gums JG, Yancey RW, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999;19:1369-77.
285. Dranitsaris G, Spizzirri D, Pitre M, McGeer A. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. Int J Technol Assess Health Care 2001;17:171-80.
286. Cadle RM, Darouiche RO, Tibbetts CS, Graviss E. Pharmacist's impact on antimicrobial drug therapy. Am J Health-Syst Pharm 1995;52:1544-6.
287. Thornton JP, Goff DA, Segal R, Guy JT. Impact of a clinical pharmacist on antibiotic prescribing: a multicenter trial. J Pharm Technol 1991;7:195-200.
288. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academy Press, 2000.
289. United States General Accounting Office. Report to congressional requesters. Adverse drug events: the magnitude of health risk is uncertain because of limited incidence data. Report no. GAO/HEHS-00-21. Washington, DC: GOA, Health, Education, and Human Services Division, January 2000.
290. National Center for Health Statistics. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Stat 1999;13(143):7.
291. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med 2000;15:149-54.
292. Leape LL. Error in medicine. JAMA 1994;272:1851-7.
293. Catellier DJ, Conlisk EA, Vitt CM, Levin KS, Menon MP, Upchurch GA. A community-based pharmaceutical care program for the elderly reduces emergency room and hospital use. N C Med J 2000;61:99-103.
294. Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy 2001;21:1023-36.
295. Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomized controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. Br Med J 2001;323:1-5.
296. Monane M, Matthias D, Nagle B, Kelly M. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA 1998;280:1249-52.
297. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA 2001;286:2823-9.
298. Borgsdorf LR, Miano JS, Knapp KK. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm 1994;51:772-7.
299. Emerson A, Martin RM, Tomlin M, Mann RD. Prospective cohort study of adverse events monitored by hospital pharmacists. Hospital adverse event monitoring study (HAEMS) group. Pharmacoepidemiol Drug Saf 2001;10:95-103.
300. Canales PL, Dorson PG, Crismon ML. Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting. Am J Health-Syst Pharm 2001;58:1309-16.
301. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.
302. Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld W. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther 1997;19:113-23.
303. Rupp MT, McCallian DJ, Sheth KK. Developing and marketing a community pharmacy-based asthma management program. J Am Pharm Assoc 1997;NS37:694-9.
304. Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs medical center. Pharmacotherapy 1998;18:1103-11.
305. Hepler CD. Regulating for outcomes as a systems response to the problem of drug-related morbidity. J Am Pharm Assoc 2001;41:108-15.
306. Cox PM Jr, D'Amato S, Tillotson DJ. Reducing medication errors. Am J Med Qual 2001;16:81-6.
307. Anonymous. ASHP therapeutic position statement on the recognition and treatment of depression in older adults. Am J Health-Syst Pharm 1998;55:2514-18.
308. Stoner SC, Worrel JA, Jones MT, et al. Pharmacist-designed and implemented pharmaceutical care plan for antipsychotic-induced movement disorders. Pharmacotherapy 2000;20:583-8.
309. Giles RE. The pharmacist's role in team treatment of patients receiving injectable long-acting fluphenazine. Hosp Pharm 11976;1:404, 407-8.
310. Gray DR, Namika EA, Sax MJ, et al. Clinical pharmacists as allied health care providers to psychiatric patients. Contemp Pharm Pract 1979;2:108-16.
311. McLeod DC. Contribution of clinical pharmacists to patient care. Am J Hosp Pharm 1976;33:904-11.
312. Evans RL, Kirk RF, Walker PW, et al. Medication maintenance of mentally ill patients by a pharmacist in a community setting. Am J Hosp Pharm 1976;33:635-8.
313. Dugus JE, Cardoni AA, Pierpaoli PG. Pharmacists should serve on psychiatric patients' units. Hospitals 1975;49:79-82.
314. Coleman JH, Evans RL, Rosenbluth SA. Extended clinical roles for the pharmacist in psychiatric care. Am J Hosp Pharm 1973;30:1143-6.
315. Ivey MF. The pharmacist in the care of ambulatory mental health patients. Am J Hosp Pharm 1973;30:599-602.
316. Kohan S, Chung SY, Stone J. Expanding the pharmacist's role in a psychiatric hospital. Hosp Community Psychiatry 21973;4:164-6.
317. Miller WA, Corcella J. New member on the team. Ment Hyg 1972;56:57-61.
318. Wells BG. Underrecognition and undertreatment of depression: what is the pharmacist's culpability? Pharmacotherapy 1999;19:1237-9.
319. Ellenor GL, Frisk AP. Pharmacist impact on drug use in an institution for the mentally retarded. Am J Hosp Pharm 1977;34:604-8.
320. Inoue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Ment Retard 1982;20:70-4.
321. Berchou RC. Effect of a consultant pharmacist on medication use in an institution for the mentally retarded. Am J Hosp Pharm 1982;39:1671-4.
322. Alexander B, Nasrallah HA, Perry P, et al. The impact of psychopharmacology education on prescribing practice. Hosp Community Psychiatry 1983;34:1150-3.
323. Saklad SR, Ereshefsky L, Jann MW, Crismon ML. Clinical pharmacists' impact on prescribing in an acute adult psychiatric facility. Drug Intell Clin Pharm 1984;18:632-4.
324. Stimmel GL, McGhan W, Wincor MZ, Deandrea DM. Comparison of pharmacist and physician prescribing for psychiatric inpatients. Am J Hosp Pharm 1982;39:1483-6.
325. Rosen CE, Holmes S. Pharmacist's impact on chronic psychiatric outpatients in community mental health. Am J Hosp Pharm 1978;35:704-8.
326. Finley PR, Rens HR, Gess S, Louie C. Case management of depression by clinical pharmacists in a primary care setting. Formulary 1999;34:864-70.
327. Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health-Syst Pharm 2002;59:1518-26.
328. Fulop G, Kelly MA, Robinson D Jr, et al. Opportunities for depression disease management: a pharmacy benefit manager's experience. Depress Anxiety 1999;10:61-7.
329. Boudreau D, Capoccia K, Sullivan S, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother 2002;36:585-91.
330. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid program. Value Health 1999;2:269-80.
331. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-30.
332. Diamond SA, Chapman DR. The impact of a nationally coordinated pharmacy-based asthma education intervention. Can Resp J 2001;8:261-5.
333. Kania D. The community pharmacist: a vital link in caring for the asthma patient. J Pharm Pract 1997;10:134-46.
334. Anonymous. Pharmacists can help improve outcome for asthma patients by monitoring inhaler use, says national committee. Am J Hosp Pharm 1993;50:584-5.
335. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. National asthma education and prevention program expert panel report 2. Available from http://www.nhlbi.nih.gov/guidelines/index. htm. Accessed May 5, 2002.
336. Vainio KK, Korhonen MJH, Hirvonen AM, Enlund KH. The perceived role and skills of pharmacist in asthma management after in-house training. Pharm World Sci 2001;23:6-12.
337. Anonymous. Pharmacists' role in drop in asthma deaths highlighted. Aust J Pharm 1998;79:1054.
338. Sterne SC, Gundersen BP, Shrivastava D. Development and evaluation of a pharmacist-run asthma education clinic. Hosp Pharm 1999;34:699-706.
339. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001;21:1196-203.
340. Herborg H, Soendergaard B, Froekjaer B, et al. Improving drug therapy for patients with asthma. I. Patient outcomes. J Am Pharm Assoc 2001;41:539-50.
341. Pagan S, Malcolm KE, Weight S, Curry JD. Assessment of quality of life in asthma patients attending a pharmacist-managed, physician-directed asthma clinic [abstr], In: Program and abstracts of the 31st midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1996:203R.
342. Lowe SS, Zietlow KA, Blumenberg TL, Lee AJ, Hamstra SA. Impact of a pharmacist managed asthma clinic on number of emergency room visits and hospital admissions at a southwest Indian health service hospital [abstr]. In: Program and abstracts of the 30th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1995:229R.
343. Scholtz D, Ballentine R. Effect of pharmacist intervention on initial drug noncompliance and emergency room visits in asthmatic patients [abstr]. In: Program and abstracts of the 25th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1990:417.
344. Hibbert D. Patient and pharmacist views of asthma care in the community pharmacy. J Soc Adm Pharm 2000;17:202-8.
345. Cairns C, Eveleigh M. Community pharmacists' contribution to managing patients with asthma. Asthma J 2000;5:80-3.
346. Sterne SC, Gundersen BP, Shrivastava D. Development and evaluation of a pharmacist-run asthma education clinic [abstr]. In: Program and abstracts of the 31st midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1996:206R.
347. Chrystyn H. Community care of asthma: the pharmacist as counselor? J Pharm Pharmacol 1997;49(suppl 3):51-4.
348. Williams DW. Pharmaceutical care for the patient with upper airway allergies and asthma [abstr]. In: Program and abstracts of the 54th annual meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1997:26.
349. O'Sullivan TL, Erickson SR, Berman J, Stevenson JG. Impact of pharmaceutical care with comprehensive education by pharmacists on outcomes of patients with asthma [abstr]. In: Program and abstracts of the 51st annual meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1994:03.
350. Hunt J, Bauman A, Taylor L, Young L, Larkin P. Reducing asthma morbidity: untapped potential of community pharmacists. Aust J Pharm 1990;71:922-4, 932.
351. Saini B, Krass I, Arnour C. Specialisation in asthma: current practice and future roles-a qualitative study of practising community pharmacists. J Soc Adm Pharm 2001;18:169-77.
352. MacDonald AF, Shea B, Powell S, et al. Creative ways to practice pharmaceutical care in an asthma clinic: six months in review [abstr]. In: Program and abstracts of the 31st midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1996:204D.
353. Narhi U, Airaksinen M, Tanskanen P, Enlund H. The effects of a pharmacy-based intervention on the knowledge and attitudes of asthma patients. Patient Educ Couns 2001;43:171-7.
354. Pinto LA. Exploring asthma patients' predictive and normative expectations of pharmacists' services and the relationship of these expectations to overall patient satisfaction [abstr]. In: Program and abstracts of the 57th annual meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 2000:44.
355. Anonymous. Pharmacists aid asthma management. Aust J Pharm 1993;74:571.
356. Schultz M, Verheyen F, Muhlig S, et al. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol 2001;41:668-76.
357. Bynum A, Hopkins D, Thomas A, Copeland N, Irwin C. The effect of telepharmacy counseling on metered-dose inhaler technique among adolescents with asthma in rural Arkansas. Telemed J E Health 2001;7:207-17.
358. Richey CE. Pharmacist's role in managing asthmatic patients in an outpatient setting [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999:105.
359. Chow CL, Nieuwoudt CD. Pharmacist as a team member in an inpatient asthma education program [abstr]. In: Program and abstracts of the 30th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1995:4360.
360. Jackevicius CA, Chapman KR. Inhaler education for hospital-based pharmacists: how much is required? Can Resp J 1999;6:237-44.
361. Bell HM, McElnay JC, Hughes CM, Gleadhill I. Primary schoolteachers' knowledge of asthma: the impact of pharmacist intervention. J Asthma 2000;37:545-55.
362. Narhi U, Airaksinen M, Tanskanen P, Erlund H. Therapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. J Clin Pharm Ther 2000;25:177-83.
363. Grainger-Rousseau TJ, McElnay JC. A model for community pharmacist involvement with general practitioners in the management of asthma patients. J Appl Ther 1996;1:145-61.
364. Herborg H, Soendergaard B, Jorgensen T, et al. Improving drug therapy for patients with asthma. II. Use of antiasthma medications. J Am Pharm Assoc 2001;41:551-9.
365. Bheekie A, Syce JA, Weinberg EG. Peak expiratory flow rate and symptom self-monitoring of asthma initiated from community pharmacies. J Clin Pharm Ther 2001;26:287-96.
366. Erickson SR, Landino HM, Zarowitz BJ, Kirking DM. Pharmacists' understanding of patient education on metered-dose inhaler technique. Ann Pharmacother 2000;34:1249-56.
367. American Pharmaceutical Association. 2002 APhA catalog. Washington, DC: APhA, 2002.
368. Narhi U, Vainio K, Ahonen R, Airaksinen M, Erlund H. Detecting problems of patients with asthma in a community pharmacy: a pilot study. J Soc Adm Pharm 1999;16:127-33.
369. Osman LM, Bond CM, MacKenzie J, Williams S. Asthma advice giving by community pharmacists. Int J Pharm Pract 1999;7:12-17.
370. Butler N, Ayres JG. Role of the community pharmacist in asthma education. Br J Pharm Pract 1987;9:202, 205.
371. Ferro LA, Im J, Iverson P, Kennedy D, McCallian DJ, Parisi J. Developing and implementing pharmacy-based asthma services. J Am Pharm Assoc 1998;38:551-65.
372. Allen K, Snider M, Pauley T, Self TH. Asthma management initiated by community pharmacists improves outcomes: two case reports. J Am Pharm Assoc 1997;37:440-2.
373. Self TH, Nahata MC. Improving outcomes in asthma: role of pharmacy. Ann Pharmacother 1997;3:495-7.
374. Shaw J, Emmerton L, Barron P, Becket G, Smith N. Asthma management: role of the pharmacist. N Z Pharm 2000;20:21-2, 24.
375. Mitchell LM, Anderson ER, Villanueva AG, Levine AS. Asthma center pharmacists role in a multidisciplinary disease management program and its
376. Albert SG, Bucey LS, Glemaud I, Migliore M, Oberg KC. Competency standards for pharmacists involved in a medication adherence clinic for asthma patients [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999;34:442.
377. Slezak M. Pharmacists lead the attack on asthma. Am Druggist 1998;215:43-4.
378. Lang GJ, Barry CP, Meyers JD. Development of a hospital pharmacy-based medication management and teaching program for emergency room asthma patients [abstr]. In: Program and abstracts of the 28th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1993:279R.
379. Scoggin JA, Marcrom R. Direct involvement of community pharmacists in the care of asthma patients: dream or a reality? J Pharm Pract 1992;5:197-203.
380. Anonymous. Pharmacists positioned to play more professional role in asthma care. Aust J Pharm 1988;69:617-18.
381. Kradjan WA, Schultz R, Christensen DB, et al. Patients' perceived benefit from and satisfaction with asthma-related pharmacy services. J Am Pharm Assoc 1999;39:658-66.
382. Sleath B, Collins T, Kelly HW, McCament-Mann L, Lien T. Effect of including both physicians and pharmacists in an asthma drug-use review intervention. Am J Health-Syst Pharm 1997;54:2197-200.
383. Morris A. Effective asthma control: time for physician and pharmacist to join forces [letter]. S Afr Med J 1997;87:908.
384. Cairns CJ, Eveleigh M. Involving community pharmacists in asthma care: lessons from a pilot study [abstr]. In: Program and abstracts of the 34th midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1999:83.
385. Knoell DL, Pierson JF, Pathak DS, Marsh CB, Allen JN. Pharmacist interventions in a comprehensive asthma clinic [abstr]. In: Program and abstracts of the 31st midyear clinical meeting of the American Society of Health-System Pharmacists. Bethesda: ASHP, 1996:556R.
386. Weiss KB, Grant EN. The Chicago asthma surveillance initiative: a community-based approach to understanding asthma care. Chest 1999;116(4 suppl 1):S141-5.
387. McElnay JC, Maguire TA, Drummond A, Hughes CM. Smoking cessation: the contribution of community pharmacy. Dis Manag Health Outcomes 2000;8:147-58.
388. Kennedy DT, Small RE. Development and implementation of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc 2002;42:83-92.
389. Kennedy DT, Giles JT, Chang ZG, Small RE, Edwards JH. Results of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc 2002;42:51-6.
390. Zillich AJ, Ryan M, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy 2002;22:759-65.
391. Ryan-Woolley BM, Cantrill JA. Professional perspective on a feasibility study of GP-pharmacist collaboration in the management of angina. Int J Pharm Prac 2000;8:275-84.
392. McNeill A, Armstrong M. The impact of amfebutamone (bupropion) on National Health Service smoking cessation services. Pharm J 2000;265:860-2.
393. Smith MD, McGhan WF, Lauger G. Pharmacist counseling and outcomes of smoking cessation. Am Pharm 1995;35:20-9, 32.
394. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at 'real world' patch users. JAMA 1994;271:601-7.
395. Baluch WM. Pharmacists' role in a smoking-cessation program at a health maintenance organization. Am J Health-Syst Pharm 1995;52:287-93.
396. Gauen SE, Lee NL. Pharmacists' role in a smoking-cessation program at a managed health care organization. Am J Health-Syst Pharm 1995;52:294-6.
397. Tommasello T. Two pharmacy-practice models for implementing the AHCPR smoking cessation guideline. Tob Control 1997;6(suppl 1):36-8.
398. Sinclair HK, Bond CM, Lennox AS, et al. Training pharmacists and pharmacy assistants in the stage-of-change model of smoking cessation: a randomised controlled trial in Scotland. Tob Control 1998;7:253-61.
399. Crealey GE, Mcelnay JC, Maguire TA, Oneill C. Costs and effects associated with a community pharmacy-based smoking-cessation program. Pharmacoeconomics 1998;14:323-33.
400. McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health-Syst Pharm 1996;53:45-52.
401. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Service, Public Health Service, June 2000.
402. Anderson C. A controlled study of the effect of a health promotion training scheme on pharmacists' advice about smoking cessation. J Soc Admin Pharm 1995;12:115-24.
403. Morton WA. Chemical dependence: a look at what does and doesn't work. J Pharm Prac 1996;9:147-54.
404. Carmichael JM, O'Connell MB, Devine B, et al, for the American College of Clinical Pharmacy. Collaborative drug therapy management by pharmacists. Pharmacotherapy 1997;17:1050-61.
405. Hammond RW, Schwartz AH, Campbell MJ, et al, for the American College of Clinical Pharmacy. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy 2003;23:1210-25.